These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 20215520)

  • 1. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
    Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
    Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
    Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
    J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
    Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
    Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
    Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
    Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
    J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
    Sleijfer S; Gorlia T; Lamers C; Burger H; Blay JY; Le Cesne A; Scurr M; Collin F; Pandite L; Marreaud S; Hohenberger P
    Br J Cancer; 2012 Aug; 107(4):639-45. PubMed ID: 22805326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
    Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
    Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of 16 serum angiogenic factors in stage I non-small cell lung cancer using a bead-based multiplex immunoassay.
    Klupczynska A; Dereziński P; Matysiak J; Dyszkiewicz W; Kasprzyk M; Kokot ZJ
    Biomed Pharmacother; 2017 Apr; 88():1031-1037. PubMed ID: 28192876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
    Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G
    Am J Clin Oncol; 2020 Sep; 43(9):621-627. PubMed ID: 32889831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
    Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
    Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib in ovarian cancer.
    McLachlan J; Banerjee S
    Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations.
    Hu M; Zhang T; Gu M; Li J; Zhang H; Wang Q; Hu F; Yang Y; Li B
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):798-803. PubMed ID: 33347392
    [No Abstract]   [Full Text] [Related]  

  • 16. [Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].
    Swidzińska E; Naumnik W; Chyczewska E
    Pneumonol Alergol Pol; 2006; 74(4):414-20. PubMed ID: 17427152
    [No Abstract]   [Full Text] [Related]  

  • 17. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
    Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
    Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis and antiangiogenic agents in non-small cell lung cancer.
    Galligioni E; Ferro A
    Lung Cancer; 2001 Dec; 34 Suppl 4():S3-7. PubMed ID: 11742695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
    Necchi A; Pennati M; Zaffaroni N; Landoni E; Giannatempo P; Raggi D; Schwartz LH; Morosi C; Crippa F; Farè E; Nicolai N; Lanocita R; Sava T; Sacco C; Messina C; Ortega C; De Braud FG; Salvioni R; Daidone MG; Gianni AM; Mariani L
    Br J Cancer; 2014 Jan; 110(1):26-33. PubMed ID: 24231947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.